Aurinia Pharmaceuticals Inc. (AUPH) Financial Statements
Aurinia Pharmaceuticals Inc. (AUPH) reported trailing twelve-month revenue of $311.5M (up 19.8% year on year) and net income of $314.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $175.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AUPHAurinia Pharmaceuticals Inc.Follow AUPH — free
—
Price chart with a free account
- Market cap
- 2.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4 | 0.5 | 0.3 | 50.1 | 45.6 | 134.0 | 175.5 | 235.1 | 283.1 | 311.5 | |
| Gross profit | — | — | — | — | 44.5 | 128.4 | 161.4 | 206.9 | 250.4 | 281.5 | |
| Research & development | — | — | — | 50.3 | 51.1 | 45.0 | 49.6 | 20.8 | 32.5 | 39.9 | |
| Operating income | — | — | — | -104.3 | -180.7 | -111.5 | -91.7 | -4.7 | 104.9 | 150.7 | |
| Pre-tax income | — | -64.0 | -123.7 | -102.8 | -180.2 | -106.4 | -77.5 | 7.4 | 114.2 | 160.4 | |
| Income tax | — | — | — | -0.1 | 0.8 | 1.8 | 0.6 | 1.7 | -173.0 | -153.8 | |
| Net income | — | — | — | -102.7 | -181.0 | -108.2 | -78.0 | 5.8 | 287.2 | 314.1 | |
| Diluted EPS ($) | — | — | — | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.07 | 2.29 | |
| Diluted shares (mn) | — | — | — | — | — | 141.9 | 143.2 | 146.2 | 138.7 | — |
USD millions · SEC XBRL
Aurinia Pharmaceuticals Inc. — questions
- What is Aurinia Pharmaceuticals Inc.'s revenue?
- $311.5M over the twelve months to 2026-06-30, up 19.8% year on year, from its 10-Q and 10-K filings.
- What is Aurinia Pharmaceuticals Inc.'s net income?
- $314.1M over the twelve months to 2026-06-30.
- What is Aurinia Pharmaceuticals Inc.'s free cash flow?
- $175.1M over the twelve months to 2026-06-30.
- What are Aurinia Pharmaceuticals Inc.'s diluted earnings per share?
- $2.29 over the twelve months to 2026-06-30.
Every figure on this page comes from Aurinia Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.